CA3206486A1 - Antiviral agent - Google Patents
Antiviral agentInfo
- Publication number
- CA3206486A1 CA3206486A1 CA3206486A CA3206486A CA3206486A1 CA 3206486 A1 CA3206486 A1 CA 3206486A1 CA 3206486 A CA3206486 A CA 3206486A CA 3206486 A CA3206486 A CA 3206486A CA 3206486 A1 CA3206486 A1 CA 3206486A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- strain
- carbons
- alkyl group
- antiviral agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-007531 | 2021-01-20 | ||
| JP2021007531 | 2021-01-20 | ||
| PCT/JP2022/001997 WO2022158528A1 (ja) | 2021-01-20 | 2022-01-20 | 抗ウイルス剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206486A1 true CA3206486A1 (en) | 2022-07-28 |
Family
ID=82549509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206486A Pending CA3206486A1 (en) | 2021-01-20 | 2022-01-20 | Antiviral agent |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240131046A1 (https=) |
| EP (1) | EP4282420A4 (https=) |
| JP (1) | JPWO2022158528A1 (https=) |
| KR (1) | KR20230137361A (https=) |
| CN (1) | CN116761615A (https=) |
| AU (1) | AU2022210132A1 (https=) |
| CA (1) | CA3206486A1 (https=) |
| WO (1) | WO2022158528A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117820248A (zh) * | 2021-04-14 | 2024-04-05 | 盐野义制药株式会社 | 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 |
| CN116782904A (zh) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | 含有三嗪衍生物的医药组合物 |
| CA3233206A1 (en) * | 2021-09-28 | 2023-04-06 | Yuki Tachibana | Pharmaceutical composition containing triazine derivative |
| TW202320793A (zh) * | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | 含有三嗪衍生物之醫藥組合物 |
| JP7253866B1 (ja) * | 2021-11-24 | 2023-04-07 | 塩野義製薬株式会社 | トリアジン誘導体を含有する経口投与する製剤 |
| WO2023054732A2 (ja) * | 2022-01-19 | 2023-04-06 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
| WO2024076951A2 (en) * | 2022-10-04 | 2024-04-11 | The Scripps Research Institute | Antiviral prodrugs and formulations thereof |
| JPWO2024075794A1 (https=) * | 2022-10-04 | 2024-04-11 | ||
| CN117357531A (zh) * | 2023-09-08 | 2024-01-09 | 湖北九康通生物医药有限公司 | 一种药物组合物、其制备方法和其应用 |
| CN117417387A (zh) * | 2023-09-13 | 2024-01-19 | 苏州翔实医药发展有限公司 | 一种核苷类似物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US11738025B2 (en) * | 2020-02-04 | 2023-08-29 | Oyagen, Inc. | Method for treating coronavirus infections |
| MX2022012360A (es) * | 2020-04-01 | 2022-10-21 | Union Therapeutics As | Tratamiento. |
| KR20210151949A (ko) * | 2020-04-05 | 2021-12-14 | 화이자 인코포레이티드 | Covid-19의 치료를 위한 화합물 및 방법 |
| IL297319A (en) * | 2020-04-13 | 2022-12-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Use of metabolic regulators for the treatment of covid-19 |
| EP3930730A4 (en) * | 2020-04-15 | 2022-05-11 | Starpharma Pty Limited | PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION |
| EP3912628A1 (en) * | 2020-05-20 | 2021-11-24 | Institut de Recherche en Semiochimie et Ethologie Appliquée | Nucleoside analogues to inhibit the main protease of a coronavirus |
| US20220177982A1 (en) * | 2020-12-03 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof |
-
2022
- 2022-01-20 AU AU2022210132A patent/AU2022210132A1/en not_active Abandoned
- 2022-01-20 EP EP22742650.9A patent/EP4282420A4/en active Pending
- 2022-01-20 US US18/262,326 patent/US20240131046A1/en active Pending
- 2022-01-20 CN CN202280010804.2A patent/CN116761615A/zh active Pending
- 2022-01-20 JP JP2022576742A patent/JPWO2022158528A1/ja active Pending
- 2022-01-20 KR KR1020237027751A patent/KR20230137361A/ko active Pending
- 2022-01-20 WO PCT/JP2022/001997 patent/WO2022158528A1/ja not_active Ceased
- 2022-01-20 CA CA3206486A patent/CA3206486A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022210132A1 (en) | 2023-08-31 |
| KR20230137361A (ko) | 2023-10-04 |
| CN116761615A (zh) | 2023-09-15 |
| WO2022158528A1 (ja) | 2022-07-28 |
| EP4282420A1 (en) | 2023-11-29 |
| JPWO2022158528A1 (https=) | 2022-07-28 |
| EP4282420A4 (en) | 2024-11-27 |
| US20240131046A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3206486A1 (en) | Antiviral agent | |
| RU2718690C2 (ru) | Способы и композиции для ингибирования полимеразы | |
| RU2689984C2 (ru) | Лечение катаплексии | |
| US11364256B2 (en) | Viral inhibition | |
| US12161610B2 (en) | Method of viral inhibition | |
| AU2025205085A1 (en) | Agents and methods for modulating pathogen activity | |
| JP2025517992A (ja) | デング感染の治療のための投薬レジメン | |
| JP2009522257A (ja) | ウイルス感染症治療用薬剤 | |
| HK40104268A (en) | Anti-viral agent | |
| WO2013111013A2 (en) | Methods for treating alzheimer's disease by administering certain synthetic compounds | |
| WO2022170396A1 (en) | Agents and methods for therapy and prophylaxis | |
| EP4431100A1 (en) | Antiviral agent | |
| JP7758278B2 (ja) | コロナウイルス科感染症の治療又は予防 | |
| JP2023072634A (ja) | 抗ウイルス剤 | |
| KR20150085966A (ko) | 센노사이드 a를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물 | |
| CN117503776A (zh) | 一种药物组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241216 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |